C4 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on May 15, 2026, covering events occurring on May 12, 2026. The filing addresses a change in the Company's principal accounting officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Mark Mossler ceased serving as Chief Accounting Officer effective May 15, 2026.
- Reason for Departure: The departure is not due to any disagreement with the Company or its Board regarding financial reporting, operations, policies, or practices.
- Appointment: Kendra R. Adams, currently the Chief Financial Officer, Head of Corporate Affairs, and Treasurer, was designated as the new Principal Accounting Officer effective May 15, 2026.
- Compensation: Ms. Adams will not receive additional compensation for this new role, and no changes were made to her existing plans or arrangements.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No new risks or contingencies were disclosed in this report. The Company noted that Ms. Adams' background and contract details are incorporated by reference from the 2026 definitive proxy statement filed on April 29, 2026.
Investor Verification Checklist
- Verify the effective date of the Chief Accounting Officer transition (May 15, 2026).
- Confirm that the departure of the previous officer was not related to financial reporting disagreements.
- Review the 2026 definitive proxy statement (filed April 29, 2026) for details on Kendra R. Adams' background and compensation.
- Monitor future filings for any impact on the Company's financial reporting timeline due to the leadership change.